S&P 500   3,960.50 (-0.08%)
DOW   33,702.87 (-0.23%)
QQQ   284.46 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.84 (-4.25%)
BABA   92.36 (-1.92%)
AMD   69.64 (-1.18%)
T   19.21 (+0.47%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.24 (+0.91%)
GE   82.27 (-1.63%)
DIS   94.05 (+1.62%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.88 (+0.19%)
NFLX   325.08 (+4.78%)
S&P 500   3,960.50 (-0.08%)
DOW   33,702.87 (-0.23%)
QQQ   284.46 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.84 (-4.25%)
BABA   92.36 (-1.92%)
AMD   69.64 (-1.18%)
T   19.21 (+0.47%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.24 (+0.91%)
GE   82.27 (-1.63%)
DIS   94.05 (+1.62%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.88 (+0.19%)
NFLX   325.08 (+4.78%)
S&P 500   3,960.50 (-0.08%)
DOW   33,702.87 (-0.23%)
QQQ   284.46 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.84 (-4.25%)
BABA   92.36 (-1.92%)
AMD   69.64 (-1.18%)
T   19.21 (+0.47%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.24 (+0.91%)
GE   82.27 (-1.63%)
DIS   94.05 (+1.62%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.88 (+0.19%)
NFLX   325.08 (+4.78%)
S&P 500   3,960.50 (-0.08%)
DOW   33,702.87 (-0.23%)
QQQ   284.46 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.84 (-4.25%)
BABA   92.36 (-1.92%)
AMD   69.64 (-1.18%)
T   19.21 (+0.47%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.24 (+0.91%)
GE   82.27 (-1.63%)
DIS   94.05 (+1.62%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.88 (+0.19%)
NFLX   325.08 (+4.78%)
NASDAQ:MTCR

Metacrine - MTCR Stock Forecast, Price & News

$0.40
+0.01 (+2.74%)
(As of 12/9/2022 01:45 PM ET)
Add
Compare
Today's Range
$0.38
$0.40
50-Day Range
$0.35
$0.49
52-Week Range
$0.30
$1.73
Volume
19,000 shs
Average Volume
176,829 shs
Market Capitalization
$16.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Metacrine MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$350,865 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.62) to ($0.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

735th out of 1,022 stocks

Pharmaceutical Preparations Industry

355th out of 499 stocks

MTCR stock logo

About Metacrine (NASDAQ:MTCR) Stock

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Receive MTCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Metacrine and its competitors with MarketBeat's FREE daily newsletter.

MTCR Stock News Headlines

Metacrine, Inc.: Metacrine Reports Third-Quarter 2022 Results
Metacrine Reports Third-Quarter 2022 Results
Metacrine, Inc. (MTCR)
Metacrine: Q2 Earnings Insights - Benzinga
Metacrine Reports Second-Quarter 2022 Results
Metacrine Reports First-Quarter 2022 Results
Metacrine Reports Fourth-Quarter 2021 Results
See More Headlines
Receive MTCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Metacrine and its competitors with MarketBeat's FREE daily newsletter.

MTCR Company Calendar

Last Earnings
11/14/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/29/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MTCR
Fax
N/A
Employees
35
Year Founded
N/A

Profitability

Net Income
$-62,210,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.36 per share

Miscellaneous

Free Float
37,717,000
Market Cap
$16.94 million
Optionable
Not Optionable
Beta
-0.81

Key Executives

  • Dr. Preston S. Klassen M.D. (Age 53)
    M.H.S., Pres, CEO & Director
    Comp: $749.38k
  • Ms. Patricia Millican (Age 49)
    Chief Financial Officer
  • Ms. Theresa Lowry
    VP of HR
  • Mr. Michael B. York (Age 57)
    Chief Bus. Officer













MTCR Stock - Frequently Asked Questions

Should I buy or sell Metacrine stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Metacrine in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MTCR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MTCR, but not buy additional shares or sell existing shares.
View MTCR analyst ratings
or view top-rated stocks.

How have MTCR shares performed in 2022?

Metacrine's stock was trading at $0.6742 on January 1st, 2022. Since then, MTCR shares have decreased by 40.7% and is now trading at $0.40.
View the best growth stocks for 2022 here
.

When is Metacrine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our MTCR earnings forecast
.

How were Metacrine's earnings last quarter?

Metacrine, Inc. (NASDAQ:MTCR) issued its quarterly earnings data on Monday, November, 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.02.

What other stocks do shareholders of Metacrine own?
When did Metacrine IPO?

(MTCR) raised $84 million in an initial public offering on Wednesday, September 16th 2020. The company issued 6,500,000 shares at $12.00-$14.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Metacrine's stock symbol?

Metacrine trades on the NASDAQ under the ticker symbol "MTCR."

Who are Metacrine's major shareholders?

Metacrine's stock is owned by many different institutional and retail investors. Top institutional investors include Tang Capital Management LLC (4.04%), Tudor Investment Corp Et Al (0.82%), Vanguard Group Inc. (0.60%), Jane Street Group LLC (0.41%), Citadel Advisors LLC (0.32%) and Two Sigma Advisers LP (0.15%). Insiders that own company stock include Alexandria Venture Investments, Braden Michael Leonard, Global Strategic Fund Venbio, Hubert C Chen, Paul Edward Walker and Preston Klassen.
View institutional ownership trends
.

How do I buy shares of Metacrine?

Shares of MTCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Metacrine's stock price today?

One share of MTCR stock can currently be purchased for approximately $0.40.

How much money does Metacrine make?

Metacrine (NASDAQ:MTCR) has a market capitalization of $17.03 million. The company earns $-62,210,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis.

How can I contact Metacrine?

Metacrine's mailing address is 3985 SORRENTO VALLEY BLVD. SUITE C, SAN DIEGO CA, 92121. The official website for the company is www.metacrine.com. The company can be reached via phone at 858-369-7800 or via email at investors@metacrine.com.

This page (NASDAQ:MTCR) was last updated on 12/9/2022 by MarketBeat.com Staff